A PILL Treatment with a Trojan Horse Mechanism Is Coming for COVID-19: Covinavir (Molnupiravir)

Our hopes are growing that the day will come when just one pill can rid COVID-19 patients’ bodies of the virus. US-based pharmaceutical companies Merck and Ridgeback announced the results of a clinical trial testing the antiviral drug molnupiravir (brand name Covinavir) against COVID-19 in phase 3. According to these results, molnupiravir potentially reduces the risk of hospitalization or death in patients with mild to moderate COVID-19 by approximately 50 percent.

The study included 775 patients with laboratory-confirmed, symptomatic COVID-19. Participants were adults with mild to moderate COVID-19 who had health conditions such as obesity, diabetes or heart disease and were considered at higher risk of severe illness.

• Approximately 7.3% of those who received Covinavir were hospitalized, compared with 14.1% of those given a placebo pill (containing no active ingredient).
• Compared with eight people in the placebo group, no one taking Covinavir lost their life within a period of 29 days.
• Furthermore, Covinavir’s activity against the most common SARS-CoV-2 variants has been demonstrated by clinical data.

Trojan Horse – The Mechanism of Action of Molnupiravir (Covinavir)

Covinavir is an antiviral agent originally developed against influenza, the virus that causes flu. In brief, its mechanism of action is to mimic nucleic acids. Cancer drugs of this type have also been used for a long time. Covinavir belongs to the class of nucleoside analogs; the virus incorporates this false molecule into its structure, mutations then accumulate in the viral genome, and viral replication is suppressed.

So What Does This Development Mean for Us?

• Clinical studies have identified an important antiviral drug that will help in treating COVID-19. It must be emphasized that the most effective ways to stop the COVID-19 Pandemic are vaccination and measures such as social distancing, masks and personal hygiene. Drugs like Covinavir may fill a critical gap in the treatment needs of people for whom vaccines are not effective, who become infected despite vaccination or who are at high risk of severe illness because of additional health conditions.
• MERCK announced that it would apply to the FDA (US Food and Drug Administration) for “emergency use authorization” of the drug very soon.
• If the FDA approves the pill containing molnupiravir, COVID-19 will have its first orally administered antiviral treatment available.
• The late-stage trial results were reported by the pharmaceutical company, but have not yet been published in a peer-reviewed medical journal.

*

Manage preferences to view external content

Manage preferences to view external content